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Abstract: The aim of the study was to evaluate the effect of Oxyjun™ on cardiovascular fitness of overweight 
individuals by reducing obesity induced systemic inflammation. Male participants between the ages of 18 - 35 years 
and body mass index of 25 - 34.9 kg/m2 were recruited in the study. Change in neutrophil lymphocyte ratio (NLR), 
high density lipoprotein (HDL-c) and quality of life using 36-item Short form survey (SF-36) was assessed over a 
period of 8-weeks. Results demonstrated that NLR was reduced by 0.71 in Oxyjun™ and by 0.42 in the placebo 
group at the end of study period. Also, within group comparison was significant for Oxyjun™ group when 
compared from baseline; p<0.001. Further, HDL-c levels were increased in the OxyjunTM group by 4.04 mg/dL and 
reduced for the placebo group by 1.22 mg/dL when compared from baseline; p=0.09. For SF-36 quality of life 
assessments, the health concepts of fatigue, mental health, and social function showed significant improvement 
and no adverse or serious adverse events were reported for both groups during the course of the study. In 
conclusion, Oxyjun™ when consumed for 8-weeks reduced NLR of study volunteers thereby demonstrating its 
potential for lowering obesity induced systemic inflammation. Oxyjun™ also increased HDL levels that could further 
promote cardiovascular fitness and prevent the risk of cardiovascular events. 
 
Keywords: Obesity, Cardiovascular fitness, Inflammation, SF-36, High density lipoprotein cholesterol, Neutrophil 
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1. Introduction 
Persistent, low-grade inflammation produces a 
steady inflammatory state throughout the body [1]. In 
recent years, research has shown that a pro-
inflammatory state observed in overweight individuals 
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is due to abnormal adipose tissue immune-system 
activation [2,3]. Neutrophil-lymphocyte ratio (NLR) has 
been considered as a novel biomarker for low grade 
inflammation and [4] has been constantly linked with 
persistent fatigue, reduced cardiovascular (CV) fitness 
and subsequent risk of CV events [5,6].  
Reports have linked increased body mass index 
(BMI) and sedentary lifestyle to persistent 
inflammation resulting in reduced cardiorespiratory 
(CResp) fitness [7-9]. A recent cross-sectional study 
reported that both, dietary patterns and 
anthropometric measures are positively associated with 
persistent inflammation. These findings were not only 
prevalent in population with metabolic syndrome but 
also for otherwise healthy individuals. Additionally, the 
study also suggested that obese people reportedly had 
a higher NLR as compared to their normal weight peers 
[10]. In a separate study, Wang and associates 
observed that diet and exercise significantly influence 
obesity-induced inflammatory markers such as NLR 
[11]. Studies on overweight individuals also have 
negatively correlated diminished peak oxygenation 
capacity (VO2 peak) with elevated total neutrophil and 
leukocyte counts [12, 13]. In a recent Japanese study, 
elevated NLR was linked to dyspnea, airway 
obstruction, and impaired exercise capacity [14]. 
Similarly, an inverse relationship has also been shown 
to exist between higher NLR, poor functional and 
exercise capacity, metabolic equivalents and left 
ventricular ejection fraction (LVEF) [15]. Additionally, 
the results of a study by Paliogiannis and associates 
stated that an increase in NLR values is associated with 
a proportionate decrease in exercise capacity of an 
individual [16]. Research is hence conclusive that the 
accumulation of excessive adipose tissue is 
characterized by low-grade inflammation that can 
negatively influence exercise capacity and cause a 
delayed cardiac recovery. As exercise has been shown 
to lower the markers of systemic inflammation [10], it 
would not be wrong to propose that a reduced exercise 
capacity could further be improved by reducing this 
persistent inflammation. 
One of the central mechanisms attributed to 
endothelial dysfunction (EDF) is obesity-induced 
systemic inflammation [17]. Altered adipose tissue and 
adipocyte function negatively influence the ability of 
the endothelium to produce nitric oxide and 
prostacyclin. This causes depletion of vasodilator, 
antithrombotic and anti-atherogenic properties 
affecting CV fitness [18] Atherosclerotic plaques having 
activated macrophages and T-cell lymphocytes multiply 
and spawn an augmented inflammatory response [19] 
further increasing the CV risk [20]. EDF has also been 
linked to the fatigued state of a person. Therefore in a 
state of disruption due to pro-inflammation, it can lead 
to diminished quality of life (QoL) and cardiac 
endurance of an individual [21, 22]. It is also worth 
mentioning, long term inflammation coincides with 
abnormally low levels of high density 
lipoproteincholesterol (HDL-c) in overweight individuals 
[23, 24]. In chronic illnesses (eg Diabetes mellitus) 
characterized by inflammation and oxidative stress, 
HDL-c acts as an anti-inflammatory molecule. As levels 
decline, its cholesterol efflux promoting effect and LDL 
oxidation preventive functions are restricted [25]. This 
dysfunction has a significant impact on an individual’s 
physical fitness levels and also contributes to the risk 
of developing coronary heart disease [26]. Research 
indicates that increased lipid transfer to HDL-c by 
lipoprotein lipase and reduced HDL-c clearance by 
hepatic triglyceride lipase results in higher HDL-c 
levels. This can be indicative of increased exercise time 
in obese or overweight people [27]. Therefore it would 
be desirable to increase HDL-c level to improve the 
CResp fitness and promote primary or secondary 
prevention of cardiac events. 
Globally, low CResp fitness and physical 
functional capacity are leading causes of disease and 
disability [28-30]. Clinical trials have repeatedly 
reported adverse CV outcomes in individuals with 
sedentary behaviour and chronic inflammation [31]. 
Therefore, this “residual inflammatory risk” has 
increasingly become a viable therapeutic target [32]. 
Presently, therapies for enhancing cardiac fitness or 
endurance include weight loss strategies, exercises and 
certain interventional therapies [33]. However, the last 
few decades have seen a surge in the investigation of 
bioactive compounds for promoting CV fitness. 
Terminalia arjuna, a well-known cardiotonic has been 
developed as a proprietary extract (Oxyjun™) by 
Enovate Biolife to harness its potential as an ergogenic 
aid [34]. The Arjuna tree bark contains a host of bio-
actives such as saponins and flavonoids that are known 
to improve CV fitness [35-37]. It has proven 
therapeutic potential in hypertension, congestive heart 
failure and ischaemic heart diseases. Its antioxidant, 
anti-ischemic, antihypertensive, anti-atherogenic and 
anti-hypertrophic effects, advocate its use as a 
potential cardiac health enhancer [33, 38-42].  In our 
previously published study, Oxyjun™ was able to 
improve the LVEF; p<0.001 of non-overweight young 
adults, that was also accompanied by a decrease in 
right ventricular myocardial performance index (MPI); 
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p<0.001 [43]. Therefore, the present study was 
designed to explore the effect of Oxyjun™ on the CV 
fitness of overweight people by decreasing obesity-
induced systemic inflammation. We would like to 
mention the study was initially intended to explore the 
effect of Oxyjun™ on aerobic fitness (maximal oxygen 
consumption - VO2Max) of recruited individuals using 
an incremental exercise test protocol. However, due to 
the emergence of coronavirus disease of 2019 (COVID-
19), we were unable to evaluate the same. 
 
2. Methods 
2.1 Ethical considerations 
 The study was approved by an independent 
ethics committee - ACEAS, registered with the Office 
for Human Research Protections in the U.S. 
Department of Health and Human Services 
(IRB00006475). Written informed consents were 
voluntarily obtained from all participants and the study 
was registered on the public clinical trials registry of 
the U.S. National Library of Medicine (clinicaltrials.gov; 
NCT No: NCT03854786). The study was performed in 
compliance with the Declaration of Helsinki and with 
the International Conference on Harmonization – Good 
Clinical Practice guidelines for clinical research. 
 
2.2 Participants 
 Male participants between 18-35 years and 
BMI 25-34.9 kg/m2 were recruited through a 
participant database. Study volunteers were non-
smokers having waist circumference (WC) > 80 cm 
and fasting blood sugar <125 mg/dL. Participants with 
a history or presence of cardiac, vascular, endocrine, 
gastrointestinal, pancreatic or neurological disorders 
were not included in the present study. Recruited 
participants needed to abstain from any form of 
physical exertion and caffeine consumption 48 hours 
before assessment visits. 
 
2.3 Intervention 
 The study interventions included - 1) 
Investigational product (IP) - Oxyjun™: Terminalia 
arjuna extract 2) Placebo: Microcrystalline cellulose. 
Study products were manufactured in the form of size 
0 capsules and packed in duly labeled high-density 
polyethylene bottles. For preserving the study blinding, 
identical placebo capsules were manufactured and 
matched for size, shape, colour, texture, and 
packaging. The participants took a single capsule (400 
mg/day) after breakfast for a period of 56 days. 
2.4 Study conduct 
 The present study was an 8-week, double 
blind, randomized, placebo-controlled study for the 
effect of Oxyjun™ in overweight but otherwise healthy 
individuals seeking cardiac fitness. The first participant 
was enrolled in January 2020 and the last participant 
assessment was completed in April 2020. Participants 
were randomized in blocks of 4 using Stats Direct 
software (version 3.1.17) to either receive Oxyjun™ or 
placebo. The blinding codes were secured in tamper-
evident, sealed envelopes and access was limited to 
authorized personnel as per Vedic Lifesciences 
standard operating procedures. In view of COVID-19 
emergence, the study was conducted virtually by 
utilizing a study specific digital diary. All blood 
specimens were collected by the central laboratory 
personnel by performing home based collections and 
IP adherence or compliance of recruited participants 
was ascertained digitally. In the event of any 
discomfort experienced, participants were instructed to 
record the event starting on the day it happened and 
also indicate in the diary when the event ended. The 
same was reviewed by the clinical investigator to 
obtain as much information as possible related to the 
events telephonically. 
 
2.5 Exploratory Outcomes 
 The present study evaluated NLR for assessing 
obesity induced systemic inflammation, High-density 
lipoprotein levels which is one of the major biochemical 
risk markers for CV events and participant QoL 
standards using a validated and widely used SF-36 
health survey questionnaire [44]. 
 
Neutrophil-Lymphocyte ratio 
 In overweight and obese individuals, 
neutrophils and lymphocytes are established markers 
for adipose tissue associated subclinical inflammation 
[45, 46]. Normal NLR values in an adult, non-geriatric, 
population in good health are between 0.78 and 3.53 
[47].  In the present study, NLR was defined as the 
absolute neutrophil count divided by the absolute 
lymphocyte count. The NLR was calculated from the 
full blood count performed on day 0 (baseline visit) 
and end of study visit (day 56) as per standard 
procedures. There were no signs of clinical infection 
observed on the day of blood collection for any of the 
study participants. 
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High-Density Lipoprotein 
 Several large-scale studies have repeatedly 
demonstrated that HDL-c is a strong and inverse 
predictor of CV risk in individuals [48]. As a result, 
increasing HDL-c has emerged as an attractive tool for 
CV prevention [49]. In a recent study, Terminalia 
arjuna was shown to increase HDL-c levels from 42.34 
± 9.27 to 46.78 ± 6.52 (p < 0.001) suggesting its 
cardioprotective benefits in participants with 
dyslipidaemia [50]. In the present study, blood 
samples of participants in fasting state were collected 
on day 0 (baseline visit) and end of study visit (day 56) 
as per standard procedures. As per literature, levels 
above 40 mg/dL are considered desirable and more 
than 60 mg/dL is considered to be high [51]. 
 
Short form 36 health survey questionnaire 
 SF-36 is one of the extensively validated health 
survey instrument for appraising QoL [44]. In the 
present study, it was used to assess 8 health concepts: 
Physical Functioning, Role–Physical, Bodily Pain, 
Fatigue, Role–Emotional, Social Functioning, Mental 
Health, and General Health. Scores for each dimension 
range from 0 (poor health) to 100 (good health) with 
higher scores indicating better health related QoL. The 
SF-36 questionnaire was completed by the study 
participants using a study specific digital diary on day 0 
(baseline visit) and end of study visit (day 56).  
 
2.6 Safety assessments 
 Safety was assessed in terms of AEs or serious 
adverse events (SAE) occurrences reported by the 
participants throughout the study duration. 
 
2.7 Quality assurance 
 The study was conducted in compliance with 
the ICH-GCP guidelines laid down in E6 (R2) as per 
pre-approved monitoring and auditing plan by a Vedic 
Lifesciences team, independent of the clinical 
operational team. 
 
3. Statistical analysis 
 The sample size for the present pilot study was 
chosen based on previous research [45]. A total of 46 
participants were planned to be recruited for 
completing 40 participants; estimating a drop-out rate 
of 20%. The normality and homogeneity of data 
distribution were evaluated using the Shapiro–Wilk 
test. A descriptive and exploratory analysis of the 
variables was conducted, where their distribution, 
outliers and missing data were evaluated. The 
summary (mean, standard deviation, minimum and 
maximum) and analysis of change (mean difference, 
standard deviation) of exploratory parameters was 
compiled using Analysis of Variance (ANOVA) and 
Paired Sample T test. Due to the COVID-19 outbreak, 
only 15 participants could be recruited (1 participant 
dropped out). Haematological data of 11 participants 
was analyzed for NLR and HDL-c parameters whereas, 
SF-36 QoL questionnaire data was analysed for 14 
participants. All the statistical procedures were 
performed using the Statistical Package for the Social 
Sciences program (SPSS Inc., Chicago, United States), 
version 20.0. The level of statistical significance was 
set at p<0.05. 
 
4. Results 
 A total of 22 participants were screened, 2 
participants not satisfying the inclusion/exclusion 
criteria were deemed as screening failures. The 
number of enrolled participants was 15 as 5 
participants could not visit the site for randomization 
visits. Participants were segregated as per the 
availability of data. Eleven participants (Oxyjun™: 5; 
Placebo: 6) were assessed for haematological 
parameters and data for 14 participants (Oxyjun™: 7; 
Placebo: 7) was analysed for SF-36 health survey 
questionnaire. Figure 1 provides the study participant 
disposition. During the study, one participant dropped 
out due to personal reasons and we could not perform 
blood sample collection for 3 participants due to 
countrywide Covid-19 lockdown. 
 
4.1 Demographics and screening characteristics 
 At screening, the mean (SD) age for 
participants in Oxyjun™ and placebo group was 26.38 
(5.63) and 22.43 (5.03) years. The mean BMI (SD) 
was 29.32 (1.00) and 28.86 (1.84) kg/m2 for the 
Oxyjun™ and Placebo groups respectively. Similarly, 
waist circumference for Oxyjun™ and placebo was 
97.92 ± 4.13 cm and 96.45 ± 6.09 cm. Furthermore, 
baseline assessments of pulse rate and blood pressure 
were within normal levels for both groups and HDL-c 
levels in Oxyjun™ had a mean value of 37.46 mg/dL 
whereas the placebo group levels were on the higher 
side with a mean of 40.79 mg/dL. Other than absolute 
lymphocyte count (p=0.026) and NLR (p=0.05) the 
two groups were comparable in terms of baseline 
characteristics. Table 1 provides the screening and 
baseline characteristics for the randomized population. 
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4.2 Adipose tissue inflammation - 
Neutrophil to lymphocyte ratio 
 For the NLR ratio, values were higher at 
baseline in Oxyjun™ group as compared to placebo; 
p=0.07. After 56 days of IP administration, the NLR 
was reduced by 0.71 in the Oxyjun™ group and by 
0.42 in the placebo group; p=0.32. The within group 
comparison for NLR of Oxyjun™ was statistically 
significant when compared from day 0 to 56; p<0.01 
and the observed reduction in NLR for the placebo arm 
was approximately 50% lower than that of Oxyjun™; 
p=0.11. However, the between group comparison did 
not achieve significant difference at the end of day 56; 
p=0.28 Table 2 provides summary of NLR as 
compared from day 0 to 56. 
 
 
 
4.3 Lipid profile - High Density Lipoprotein 
 The HDL-c levels although lower in the 
Oxyjun™ group at baseline, increased by 4.04 mg/dL 
at day 56, comparatively, the HDL-c level reduced by 
1.22 mg/dL in the placebo group. The change when 
compared between both groups was nearing 
significance at the end of 56 days; p=0.09.  Table 3 
provides a summary and change in HDL-c levels as 
compared from day 0 to 56. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline (Day 0) 
Day 28 
 
Day 56 
 
1 – Lost to follow-up 
 
 
 
For QoL parameters  
Oxyjun™ (n - 7)  
Placebo (n - 7) 
 
Figure 1 Flow of study participants 
Pre-randomization drop out (n=05) 
For quality of life parameter 
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Table 1  Screening and demographic characteristics 
Groups Oxyjun™ (n=8) Placebo (n=7) 
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Screening Characteristics 
Age (Years) 26.38 5.63 27.00 20.00 34.00 22.43 5.03 20.00 18.00 30.00 0.18 
BMI (kg/m2) 29.32 1.00 29.33 28.10 30.90 28.86 1.84 28.56 26.96 31.60 0.55 
Waist 
(cm) 
97.92 4.13 98.92 91.50 102.67 96.45 6.09 95.67 87.00 105.50 0.59 
Pulse Rate 
(beats per 
minute) 
73.00 7.75 72.50 64.00 83.00 80.57 5.03 78.00 75.00 87.00 0.05 
Resting 
Systolic BP 
(mmHg) 
126.67 5.40 128.00 116.00 132.67 123.00 8.79 126.00 111.00 134.00 0.34 
Resting 
diastolic BP 
(mmHg) 
81.29 6.42 82.33 70.00 90.00 77.14 7.03 76.00 68.00 87.00 0.25 
FBG (mg/dL) 89.18 7.69 91.25 73.10 98.00 86.80 6.39 86.00 75.40 93.90 0.53 
Haemoglobin 
(g/dL) 
14.25 1.24 14.40 12.50 15.70 14.39 1.32 14.60 12.20 15.70 0.84 
Baseline Characteristics 
Waist (cm) 98.02 4.22 98.75 91.75 102.75 96.44 6.07 96.50 86.50 105.50 0.57 
Pulse Rate 
(Beats / 
minute) 
75.50 8.72 73.50 62.00 91.00 74.57 8.96 76.00 63.00 89.00 0.84 
BP Systolic 
(mmHg) 
117.50 10.41 114.00 110.00 140.00 112.29 7.25 112.00 102.00 122.00 0.29 
BP Diastolic 
(mmHg) 
78.50 8.60 80.00 64.00 90.00 72.57 9.00 70.00 60.00 84.00 0.22 
HDL (mg/dL) 37.46 4.17 38.50 30.00 42.30 40.79 8.10 44.00 28.90 50.60 0.33 
WBC 
(/cmm) 
6892.50 1760.49 6540.00 4480.00 9960.00 7545.71 2469.62 6790.00 4660.00 12600.00 0.56 
Abs. 
Lymphocytes 
(/cmm) 
1767.16 296.89 1852.85 1291.30 2099.30 2480.01 743.82 2562.10 1360.70 3641.40 0.03 
Abs. 
Neutrophils 
(/cmm) 
4213.75 1443.56 4129.95 2400.00 6840.00 4099.60 1526.13 3560.00 2651.50 6993.00 0.88 
NLR 2.39 0.74 2.34 1.40 3.48 1.68 0.46 1.76 1.02 2.30 0.05 
n – number of participants, SD – Standard deviation, Min – minimum, max – maximum, /ccm - per 
cubic millimetre, HDL – High density lipoprotein, WBC – White blood cells, Abs. – Absolute, BP- Blood 
pressure, NLR - neutrophils lymphocytes ratio, BMI – Body mass index.  
Values are presented as mean (SD). 
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Table 3 Summary of High Density Lipoprotein 
Variables 
Mean SD Min Max Mean SD Min Max Mean SD Min Max p 
value** Day 0 Day 56 Change in HDL-c 
Oxyjun™ (n=5) 38.24 3.67 33.20 42.30 42.28 6.69 31.40 49.10 4.04 4.11 -1.80 8.80 0.09 
Placebo (n=6) 40.25 8.73 28.90 50.60 39.03 7.24 27.50 47.10 -1.22 4.85 -5.80 5.30 0.57 
p value* 0.64 0.46 0.09  
n – number of participants, SD – Standard deviation, Min – minimum, Max – maximum. 
p* – ANOVA (Inter-group) and p** - Paired sample T test (Intra group).  
Values are presented as mean (SD). 
  
Table 4 Summary of SF-36 Health Survey Questionnaire 
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Physical 
function 
Day 0 Day 56 Change in Physical function score 
Oxyjun™ 
(n=7) 
55.00 20.00 30.00 85.00 49.29 33.59 10.00 100.00 -5.71 51.43 -75 70 0.78 
Placebo 
(n=7) 
65.71 10.97 50.00 75.00 60.00 25.50 25.00 100.00 -5.71 30.34 -45.00 35.00 0.64 
p value* 0.24 0.51 1.00  
Role – 
Physical 
health 
Day 0 Day 56 
Change in Role limitation due to 
Physical health 
Oxyjun™ 
(n=7) 
46.43 33.63 0.00 100.00 42.86 27.82 0.00 75.00 -3.57 46.61 -75.00 75.00 0.85 
Placebo 
(n=7) 
46.43 36.60 0.00 100.00 53.57 41.90 0.00 100.00 7.14 27.82 -25.00 50.00 0.52 
p value* 1.00 0.58 0.61  
Role – 
Emotional 
Day 0 Day 56 
Change in Role limitation due to 
Emotional problem 
Oxyjun™ 
(n=7) 
61.90 29.99 33.33 100.00 47.62 57.14 37.09 0.00 100.00 57.14  -4.76  35.64 0.74 
Placebo  
(n=7) 
47.62 42.41 0.00 100.00 57.14 37.09 0.00 100.00 9.52 41.79 -33.34 66.67 0.57 
Table  2  Summary of Neutrophil to lymphocyte ratio 
Variables 
Mean SD Min Max Mean SD Min Max Mean SD Min Max 
p value** 
Day 0 Day 56 Change in NLR 
Oxyjun™ 
(n=5) 
2.31 0.62 1.70 3.25 1.60 0.46 1.12 2.33 -0.71 0.17 -0.92 -0.53 < 0.01 
Placebo (n=6) 1.64 0.49 1.02 2.30 1.22 0.68 0.60 2.40 -0.42 0.54 -1.09 0.48 0.11 
p value* 0.07 0.32 0.28  
n – number of participants, SD – Standard deviation, Min – minimum, Max – maximum. 
p* – ANOVA (Inter-group) and p** - Paired sample T test (Intra group).  
Values are presented as mean (SD). 
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p value 0.48 1.00 0.50  
Fatigue Day 0 Day 56 Change in Fatigue 
Oxyjun™ 
(n=7) 
56.43 15.74 40.00 85.00 74.29 14.84 50.00 90.00 17.86 12.20 5.00 35.00 0.01 
Placebo 
(n=7) 
56.43 14.06 30.00 70.00 57.86 8.09 45.00 70.00 1.43 20.15 -20.00 40.00 0.86 
p value* 1.00 0.02 0.09  
Mental 
Health 
Day 0 Day 56 Change in Mental health 
Oxyjun™ 
(n=7) 
66.29 15.12 44.00 84.00 78.29 16.63 48.00 96.00 12.00 12.65 0.00 32.00 0.05 
Placebo 
(n=7) 
69.14 14.37 44.00 84.00 68.57 13.15 52.00 88.00 -0.57 17.04 -28.00 20.00 0.93 
p value* 0.72 0.25 0.14  
Social 
function 
Day 0 Day 56 Change in Social functioning 
Oxyjun™ 
(n=7) 
66.07 17.25 50.00 100.00 82.14 14.17 62.50 100.00 16.07 13.91 0.00 37.50 0.02 
Placebo 
(n=7) 
80.36 20.23 50.00 100.00 71.43 23.62 25.00 100.00 -8.93 37.99 -75.00 50.00 0.56 
p value* 0.18 0.32 0.13  
Pain Day 0 Day 56 Change in Pain 
Oxyjun™ 
(n=7) 
65.71 19.13 45.00 100.00 81.07 18.87 55.00 100.00 15.36 23.91 -10.00 52.50 0.14 
Placebo 
(n=7) 
72.50 23.67 45.00 100.00 79.29 25.93 47.50 100.00 6.79 21.39 -27.50 42.50 0.43 
p value* 0.57 0.89 0.49  
General 
Health 
Day 0 Day 56 Change in General health 
Oxyjun™ 
(n=7) 
65.00 14.14 50.00 90.00 62.86 5.67 55.00 70.00 -2.14 15.24 -35.00 10.00 0.24 
Placebo 
(n=7) 
65.71 18.80 35.00 85.00 73.57 14.06 50.00 90.00 7.86 16.04 -10.00 30.00 0.72 
p value* 0.94 0.09 0.26  
n – number of participants, min – minimum, max – maximum, SD – standard deviation. 
p* – ANOVA (Inter-group) and p** - Paired sample T test (Intra group). 
Values are presented as mean (SD). 
 
4.4 Quality of life by SF-36 Health Survey 
 Participants in the Oxyjun™ group reported 
reduced fatigue levels as indicated by a significant 
increase in Fatigue score as compared from baseline; 
p=0.02. In comparison, the scores in the placebo 
group remained more or less the same. Furthermore, 
body pain scores for Oxyjun™ and placebo group at 
baseline were 65.71 (19.13) and 72.50 (23.67) which 
at day 56 increased to 81.07 (18.87) and 79.29 (25.93) 
respectively. This indicates there was optimum relief 
from pain experienced by the Oxyjun™ group of 
participants at the end of day 56. Similar improvement  
 
was observed in mental health, social function and 
general health parameters of SF-36 in the Oxyjun™ 
group of participants. Comparatively, the mean (SD) 
physical function score for Oxyjun™ and placebo was 
55.00 (20.00) and 65.71 (10.97) and on day 56 scores 
were reduced to 49.29 (33.59) & 60.00 (25.50) 
respectively. Table 4 provides the summary and 
change in the SF-36 questionnaire as compared from  
day 0 to 56. 
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4.5 Adverse event reporting and IP 
compliance 
 None of the exposed participants reported AE 
or SAE during the entire course of the study. The 
treatment compliance was measured as >95% in 
Oxyjun™ and placebo groups respectively. None of the 
study participants dropped out due to non-compliance 
in the present study. 
 
5. Discussion 
 CResp fitness has been strongly linked to 
sustained inflammation which is a pivotal risk factor for 
cardiac dysfunction [52]. Obese or overweight 
individuals are predisposed to a pro-inflammatory state 
via increased inflammatory mediators. They show 
reduced levels of adiponectin that have an anti-
inflammatory effect under homeostatic conditions [53]. 
Consequently, high adiposity-linked chronic 
inflammation has been described as a major 
contributor to cardiorespiratory fitness [54, 55]. In a 
study by Lewis et al, effect of rice bran arabinoxylan 
compound was evaluated on NLR and other biomarkers 
in adults with non-alcoholic fatty liver disease. After 90 
days the NLR reduced to 1.4 ± 0.7 from baseline levels 
of 1.5 ± 0.6; p>0.05 [56]. In a separate study, the 
effect of Omega fatty acid was assessed on platelet 
lymphocyte ratio (PLC) and NLR in patients with 
percutaneous coronary intervention. Results indicated 
that PLC was significantly reduced after consumption 
of high dose Omega-3. However, there was no 
reduction observed in NLR of study participants [57]. 
In the present study, we evaluated systemic 
inflammation using NLR parameter, a routinely 
available non-invasive diagnostic marker. The values 
were on a higher side on baseline (2.31) and after 56 
days of Oxyjun™ administration, the NLR was reduced 
by 0.71 in the Oxyjun™ group and the within group 
comparison for Oxyjun™ was also significant; p<0.01. 
Literature suggests that NLR shares an intimate 
relationship with cardiac performance and an increase 
in its levels has been conclusively linked to fatigue, 
exhaustion or stress [58]. In previous studies, elevated 
levels of neutrophils and lymphocytes have been linked 
with low levels of physical activity and cardiac 
endurance. Thus, NLR, though being a ratio of two 
different yet complementary immune pathways [59] 
could serve as an excellent candidate for improving 
Cresp fitness and endurance [60]. Furthermore, an 
increase in NLR has also been associated with the 
pathophysiological mechanism of EDF [61]. Low 
cardiorespiratory fitness contributes to EDF and 
atherosclerosis in overweight individuals as opposed to 
their normal weight peers. Thus, an early reduction in 
NLR could promote its anti-inflammatory effect thereby 
improving CResp fitness and endothelial function in 
overweight individuals. 
 Several studies have investigated the influence 
of eccentric exercises, such as downhill running and 
resistance exercise on CV recovery [62, 63]. Research 
indicates that neutrophils infiltration into tissues causes 
inflammation and oxidative stress, and is also involved 
in muscle damage and delayed muscle soreness [64, 
65]. Therefore, inflammation-related biomarkers (eg 
cytokines, leukocyte counts and NLR) are used as 
physiological measures for the same [65]. Results of a 
study published in 2014 suggested that the 
development of stress-related neuromuscular fatigue is 
accelerated in overweight-obese individuals that 
correlate with autonomic dysfunction [66]. In the 
present study, the NLR levels were significantly 
reduced which may have had an effect on the cardiac 
recovery potential of participants. This also correlates 
with a significant reduction in the fatigue parameter of 
the SF-36 questionnaire [67]. Our findings are also in 
line with the results of our previous study where 
significant improvement was shown in LVEF and the 
right MPI of participants was reduced; p<0.001 [45]. 
As low LVEF and MPI are important determinants of 
fatigue and exercise capacity, [68] our results further 
justify the relationship between inflammation, fatigue 
and CResp fitness thereby strengthening our study 
findings. However, it is recommended that the 
association of these factors is intricately investigated in 
future studies. 
 HDL-c has known for its anti-atherogenic and 
anti-inflammatory activity as it inhibits cholesterol 
transport and LDL-c oxidation [69-71]. It reduces 
inflammation, promotes nitric oxide production in 
endothelial cells and also has a role in platelet 
activation and expression of adhesion molecules [72-
74]. There also exists a direct relationship between 
maximal exercise or work intensity and the 
concentration of HDL-c [75]. Therefore, raising HDL-c 
levels provides an important strategy for addressing 
CResp fitness. A study by Cooke et al reported that 
CoenzymeQ10 increased baseline HDL level of 53 ± 12 
mg/dL to 54 ± 10 mg/dL after 2-weeks [76]. A 
separate study that evaluated the antilipidemic 
properties of Vitamin K reported an increase of 1.5 
mg/dL post 56 days consumption [77]. Comparatively, 
for the present study the baseline HDL-c levels were 
on a lower side (<40) for the Oxyjun™ arm when 
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compared to placebo. Even so, after 56 days HDL-c 
levels in Oxyjun™ group were increased by 4.04 mg/dL 
(↑10.56%) and in the placebo group reduced by 1.22 
mg/dL (↓-3.03%). Raising HDL-c levels is a daunting 
proposition. Even the most widely used statin therapy 
with lifestyle and dietary changes accounts for a 5 -
10% increase in HDL-c levels [78]. Hence, our findings 
are particularly important as Oxyjun™ induced an 
increase of >10% in HDL-c levels for overweight and 
physically inactive study participants with no dietary 
and lifestyle changes.  
 With regards to safety assessments, none of 
the participants reported AEs or SAEs in the present 
study. This validates the excellent safety profile and 
tolerability of Oxyjun™ over 56 days in study 
participants. Despite of the present study confirming 
previous findings and contributing to additional 
evidence, it does have a few limitations. The SF-36 
health concepts of fatigue, mental health, and social 
function showed significant improvement and even the 
pain scores were improved. However, some 
parameters displayed no change which can be 
attributed to sudden lifestyle changes due to the 
emergence of COVID-19. Additionally, we were not 
able to evaluate the effect of Oxyjun™ on VO2Max due 
to COVID-19 pandemic which could have further 
reinforced and substantiated the present study 
findings. 
 
6. Conclusion 
 In conclusion, the present findings serve as a 
basis for the potential of Oxyjun™ in improving 
exercise capacity by the virtue of reducing adipose 
tissue induced inflammation. Oxyjun™ with its proven 
role in enhancing LVEF and MPI along with improved 
exercise capacity can further synergize the endurance 
enhancer and cardiovascular remodelling in exercising 
adults. It is recommended that the association of these 
factors is further investigated in future studies. 
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